Effect of azathioprine combined with infliximab on the efficacy and inflammatory factors in patients with Crohn's disease

LIU Kun; HOU Xuan; MA Zhufang

doi:10.3969/j.issn.1002-7386.2025.12.016

Abstract：Objective To investigate the effect of azathioprine(AZA)combined with infliximab(IFX)on the efficacy and inflammatory factors in patients with Crohn's disease(CD).Methods Seventy-four CD patients admitted from August 2022 to July 2024 were included as study objects,and they were divided into the observation group(n=37)and the control group(n=37)according to the random ball touching method.AZA was used in the control group,while AZA+IFX combined method was used in the observation group.The outcome measures included clinical efficacy,symptom remission time,coagulation function index level,inflammatory mediator level,oxidative stress index,and intestinal mucosal barrier function and adverse reactions.Results Compared with the control group,the observation group had significantly higher total effective rate 94.59％(P＜0.05).Compared with the control group,the relief time of abdominal distension(8.19±1.31 d)and the relief time of abdominal pain(6.28±1.21 d)in the observation group were significantly shorter(P＜0.05).Compared with the control group,the D-dimer(D-D)level(241.47±51.31 μg/L)and fibrinogen(FIB)level(2.25±0.41 g/L)were significantly lower in the observation group after treatment(P＜0.05).Compared with the control group,the level of tumor necrosis factor-α(TNF-α)(12.44±2.49 ng/L)and the level of interleukin-12(IL-12)(70.59±8.97 ng/L)were significantly decreased in the observation group after treatment,and IL-10 level(100.82±7.74 ng/L)was significantly higher(P＜0.05).Compared with the control group,after treatment,malondialdehyde(MDA)level(5.72±0.31 nmol/L)in the observation group was significantly lower,and superoxide dismutase(SOD)level(1.89±0.12 U/ml)was significantly higher(P＜0.05).Compared with the control group,the level of diamine oxidase(DAO)(5.33±0.34 U/L)and the level of lactic acid(4.09±0.32 mmol/L)in the observation group were significantly lower after treatment(P＜0.05).The incidence of adverse reactions in the observation group was 10.81％,which was no significant difference compared with 8.11％in the control group(P＞0.05).Conclusion The AZA+IFX combined method for the treatment of patients with CD can improve the clinical efficacy,shorten the relief time of abdominal distension and abdominal pain,reduce the levels of coagulation function index and inflammatory factors,improve the level of oxidative stress and intestinal barrier function indexes of patients,with better effect and good safety,which is worthy of clinical reference.